Manabu Muto, M.D., Ph.D., Professor
This department was founded in September 2012 as the main department of the “Kyoto University Hospital Cancer Center” established in 2007 for the first time among national and public universities. We support the functional management of the Cancer Center in the academia and promote the following: 1) specialized and cutting-edge oncology practice and education. 2) practice of clinical research and education, 3) basic oncology research, 4) translational oncology applying basic research for clinical practice, and 5) cancer bio-bank projects leading to development of the next-generation medical care.
Research and EducationIn this course, cancer research has been advanced from elucidating carcinogenic mechanisms to developing early diagnostic methods, new treatment, supportive treatment to improve QOL, and clinical application of genomic medicine. The course is particularly aimed at elucidating the molecular-level carcinogenic mechanism of esophageal squamous cell carcinoma by alcohol and developing preventive methods. New diagnostic methods using exhaled breath and near-infrared light have been developed. New concepts-based curative cancer treatment has been developed in investigator-initiated trials. Supportive treatment to prevent organ injury by anticancer drugs and chemotherapy for patients with organ dysfunction (e.g., renal dysfunction) have been developed with other departments (e.g., Nephrology, Pharmacology). Furthermore, translational researches contributing to the early approval of seeds developed by basis research departments have been projected, while clinical studies utilizing the National Database (NDB) have been advanced with social medicine courses as well as medical information sections. Graduate school students and junior residents can select suitable fields and receive specialized education. Moreover, graduate school students in “the training course to be specialized researchers who develop next-generation anticancer drugs” in the cancer professional training basic arrangement plan have actively been accepted.
Fundamental research on esophageal epithelium injuries acetaldehyde
Basic study on chemo-resistant esophageal squamous caricnoma cells
- Kikuchi O, Ohashi S, Horibe T, Kohno M, Nakai Y, Miyamoto S, Chiba T, Muto M, Kawakami K. Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma. Scientific Reports. 2016 Mar 9; 6: 22452.
- Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y, Muto M. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology 2015 Dec; 149(7): 1700-15
- Amanuma Y, Ohashi S, Itatani Y, Tsurumaki M, Matsuda S, Kikuchi O, Nakai Y, Miyamoto S, Oyama T, Kawamoto T, Whelan K, Nakagawa H, Chiba T, Matsuda T, Muto M. Protective role of ALDH2 against acetaldehyde-derived DNA damage in oesophageal squamous epithelium. Scientific Reports. 2015 Sep 16; 5: 14142
- Kikuchi O, Ohashi S, Nakai Y, Nakagawa S, Matsuoka K, Kobunai T, Takechi T, Amanuma Y, Yoshioka M, Ida T, Yamamoto Y, Okuno Y, Miyamoto S, Nakagawa H, Matsubara K, Chiba T, Muto M. Novel5-fuluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. Am J Cancer Res 2015 Jul 15; 5(8): 2431-40.
- Ohashi S, Kikuchi O, Tsurumaki M, Nakai Y, Kuriyama D, Kasai H, Horimatsu T, Miyamoto S, Shimizu A, Chiba T, Muto M. Preclinical validation of talaporfin sodium-mediated photodynamic therapy for esophageal squamous cell carcinoma. PLOS ONE 2014 Aug 4; 9(8): e103126
Therapeutic OncologyProfessor ： Manabu Muto
Associate Professor ： Shigemi Matsumoto
Program-Specific Associate Professor ： Masashi Kanai
Assistant Professor ： Shinya Ohashi ・Takahiro Horimatsu
Program-Specific Assistant Professor ： Yukiko Mori ・Tadayuki Kou ・Tomomasa Hayashi ・
TEL ： 075-751-4592
FAX ： 075-751-4594
e-mail ： firstname.lastname@example.org
URL ： http://oncology.kuhp.kyoto-u.ac.jp